Our Pricing

How Does Wegovy Work for Prescription Weight Loss?

Understanding how does Wegovy work for weight loss UK is essential before starting treatment. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural hormones to regulate appetite and blood sugar, helping patients achieve clinically significant weight reduction when combined with lifestyle changes. At Cured Pharmacy, Wegovy is available from £79.00 following a free online consultation with our UK-registered prescribers.

The Science Behind How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. When injected once weekly, semaglutide binds to GLP-1 receptors in the brain, pancreas, and gastrointestinal tract, triggering multiple physiological responses that support weight reduction.

The primary mechanism involves slowing gastric emptying, which prolongs feelings of fullness after meals, and acting on appetite centres in the hypothalamus to reduce hunger signals [1]. Additionally, Wegovy improves insulin secretion and reduces glucagon release, helping stabilise blood sugar levels that often drive cravings and overeating.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo — demonstrating the medication's significant clinical efficacy when combined with reduced-calorie diet and increased physical activity [2].

Wegovy Clinical Trial Results and Real-World Effectiveness

The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in UK populations. Across five major trials involving over 4,500 participants, semaglutide 2.4mg demonstrated consistent weight loss outcomes [2][3].

In STEP 2, which specifically studied patients with type 2 diabetes, Wegovy users achieved an average 9.6% weight reduction compared to 3.4% with placebo over 68 weeks [3]. Notably, 86.4% of participants on Wegovy lost at least 5% of their body weight — the threshold NICE recognises as clinically meaningful for reducing obesity-related health risks.

Real-world data from UK prescribing patterns shows similar outcomes, with patients maintaining weight loss when continuing treatment beyond the initial trial periods. However, individual results vary based on adherence, baseline BMI, metabolic health, and lifestyle modifications implemented alongside medication [2].

What Weight Loss Can You Expect with Wegovy?

While clinical trials showed average weight reductions of 10-15% over 68 weeks, your individual response depends on multiple factors including starting weight, adherence to dosing schedules, dietary changes, and physical activity levels [2]. Your UK prescriber will monitor progress throughout treatment and adjust your care plan accordingly, though specific outcomes cannot be guaranteed as response varies between patients.

How Does Wegovy Work Compared to Other Weight Loss Treatments?

Wegovy belongs to the GLP-1 receptor agonist class, but differs from earlier treatments in both potency and dosing. Unlike Saxenda (liraglutide), which requires daily injections, Wegovy's once-weekly administration improves convenience and adherence for many UK patients.

The key difference lies in receptor binding duration and selectivity. Semaglutide has a longer half-life than liraglutide, maintaining therapeutic levels throughout the week and producing more sustained appetite suppression [1]. Clinical head-to-head comparisons show Wegovy users typically achieve greater weight reduction than those using daily liraglutide formulations.

Newer dual-receptor treatments work through additional pathways, but Wegovy remains the most extensively studied single-pathway GLP-1 treatment with established long-term safety data in UK populations. Your prescriber will recommend the most appropriate option based on your medical history, treatment goals, and individual response to therapy.

Wegovy vs Oral Weight Loss Medications

Unlike oral treatments such as Orlistat, which works by blocking fat absorption in the digestive system, Wegovy addresses weight loss through central appetite regulation and metabolic pathways [4]. Many patients find GLP-1 treatments more effective for achieving substantial weight reduction, though oral options may suit those who prefer not to use injectable medications. All prescription weight loss treatments available at Cured Pharmacy require clinical assessment by a UK prescriber to determine suitability.

How to Use Wegovy: Dosing and Administration

Wegovy treatment follows a structured dose escalation schedule designed to minimise gastrointestinal side effects whilst building therapeutic levels. UK prescribing guidelines recommend starting at 0.25mg once weekly for four weeks, then increasing gradually to the maintenance dose of 2.4mg by week 17 [1].

Each pre-filled pen delivers a single dose injected subcutaneously into the abdomen, thigh, or upper arm. Patients rotate injection sites weekly to prevent lipodystrophy. The medication can be taken any day of the week, with or without meals, though maintaining a consistent weekly schedule optimises effectiveness.

Our superintendent pharmacist Tarun Kumar and the clinical team at Cured Pharmacy provide detailed administration guidance during your consultation, including technique demonstrations and troubleshooting common injection concerns. Proper storage at 2-8°C before first use is essential to maintain medication stability.

Who Can Use Wegovy in the UK?

NICE guidelines recommend considering GLP-1 treatments for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [5]. UK prescribers assess eligibility based on comprehensive medical history, current medications, and previous weight management attempts.

Wegovy is not suitable for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy or breastfeeding, and severe gastrointestinal disease [1]. Patients with a history of pancreatitis require careful evaluation before starting treatment.

At Cured Pharmacy, our UK-registered clinical team conducts thorough assessments during the free online consultation to ensure Wegovy is appropriate and safe for your individual circumstances. Treatment requires ongoing monitoring, and prescribers may adjust or discontinue therapy if adequate weight loss is not achieved or side effects become problematic.

Medical Conditions and Wegovy Suitability

Patients with type 2 diabetes can use Wegovy, though dosing may differ from those using semaglutide specifically for glycaemic control. Those with cardiovascular disease may benefit from additional protective effects observed in STEP trials, where Wegovy users showed improvements in blood pressure and lipid profiles alongside weight reduction [2]. Your prescriber will evaluate your complete medical profile to determine if Wegovy aligns with your health needs and treatment goals.

Wegovy Side Effects and What to Expect

The most common side effects reported in clinical trials are gastrointestinal, including nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [2]. These symptoms typically occur during dose escalation and diminish as the body adapts to treatment, which is why the gradual titration schedule is essential.

Less common but serious side effects include pancreatitis, gallbladder problems, and changes in heart rate. The MHRA requires monitoring for signs of thyroid tumours, though the absolute risk remains very low in human populations [1]. Patients should report persistent abdominal pain, visual changes, or severe gastrointestinal symptoms to their prescriber immediately.

Managing side effects involves practical strategies: eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on the same day each week. Most patients find symptoms manageable and do not discontinue treatment, though individual tolerance varies. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey, with access to pharmacist advice via phone on (+44) 116 4646009.

Scientific References

1. European Medicines Agency. (2021). Wegovy (semaglutide): Summary of Product Characteristics. EMA/CHMP. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. National Institute for Health and Care Excellence. (2022). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. Clinical guideline [CG189]. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.